Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.9K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.9K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.6K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

4.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of once-daily ICS/LAMA/LABA triple therapy versus ICS/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial.

The journal of allergy and clinical immunology. Global·2026
Same author

Reply to Siddiqui et al., Godbout et al., and to Chang and Mao.

American journal of respiratory and critical care medicine·2026
Same author

Targeting disease activity to predict and prevent damage in obstructive airway diseases.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort study.

The Lancet. Respiratory medicine·2026
Same author

Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma.

Allergy·2026
Same author

After the escalator: Narrative review of biomarker-guided asthma care.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026

Related Experiment Video

Updated: Mar 18, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K

Emerging Biologics in Severe Asthma.

Ian D Pavord1, Bart Hilvering2, Rahul Shrimanker1

  • 1Department of Respiratory Medicine, University of Oxford, Old Road, Oxford, OX3 7LE, UK; Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford, OX3 7FZ, UK.

Immunology and Allergy Clinics of North America
|July 13, 2016
PubMed
Summary

This study examines the eosinophilic endotype of asthma, characterized by elevated eosinophils and responsiveness to treatments targeting them. Further research into eosinophil activity and molecular signatures is recommended for better identification.

Keywords:
Anti-IL-13Anti-IL-4&13Anti-IL-5BiomarkersSevere asthmaType-2 cytokines

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K
Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

847

Related Experiment Videos

Last Updated: Mar 18, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K
Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

847

Area of Science:

  • Pulmonology
  • Immunology
  • Allergy

Background:

  • Asthma is a complex respiratory disease with diverse clinical presentations.
  • Asthma can be categorized into distinct endotypes based on inflammation, severity, and treatment response.
  • The eosinophilic endotype is a significant subtype requiring specific diagnostic and therapeutic considerations.

Purpose of the Study:

  • To define and explore the characteristics of the eosinophilic asthma endotype.
  • To highlight the role of eosinophils in the pathophysiology of this asthma subtype.
  • To discuss potential diagnostic markers and therapeutic strategies for eosinophilic asthma.

Main Methods:

  • Review of existing literature on asthma endotypes, focusing on eosinophilic asthma.
  • Analysis of clinical characteristics, including sputum and blood eosinophil counts.
  • Discussion of treatment responses in patients with elevated eosinophils.

Main Results:

  • Eosinophilic asthma is defined by persistent elevation of eosinophils in sputum and/or blood.
  • This endotype demonstrates a significant response to therapies aimed at reducing eosinophil levels.
  • Eosinophil activity, not just numbers, may be crucial and warrants further investigation.

Conclusions:

  • The eosinophilic endotype of asthma is a clinically relevant classification.
  • Identifying this endotype is key for effective, targeted treatment strategies.
  • Transcriptomic and metabolomic signatures may offer novel approaches for endotype identification.